EN DE
Watch Indo Us Bio-Tech Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Indo Us Bio-Tech Limited (INDOUS) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Indo Us Bio-Tech Limited stock ₹90.90, price ₹66.20, upside +37.3%, quality 47 out of 100. Rating: undervalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials IN

IU Indo Us Bio-Tech Limited logo Thin data Nov 15, 2026

Indo Us Bio-Tech Limited

INDOUS · NSE

Cheap (27% below fair value), but weak company and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value ₹90.90 · Undervalued 
Solidly profitable · 10.2% net margin (TTM) 
Low debt 
Quality 47/100 
Expensive Growth (revenue 3y +21.4 %/yr in INR) 
Mixed vs. peers (7/12) 
Moderate moat 54/100 · thin data
Profit last quarter 36% below a year ago. 
Falling price (downtrend) 
Negative free cash flow 
Thin data 
⟳ Cyclical⚠ Small free float
Watch Indo Us Bio-Tech Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹376.10 ₹60.31 Fair Value ₹90.90 Sep 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

26‑month range ₹60.31 – ₹376.10 · fair‑value band ₹45.12 – ₹155.30 · the ₹66.20 price screens below the ₹90.90 fair value. As of Nov 15, 2026.

Follow Indo Us Bio-Tech in your weekly email

Every Wednesday you see whether Indo Us Bio-Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Indo Us Bio-Tech Limited engages in the production, processing, packing, and marketing of seeds in India.

Show moreShow less

The company offers vegetable seeds, such as tomato, okra, bottle gourd, brinjal, carrot, cluster bean, bitter gourd, ridge gourd, cucumber, cabbage, radish, sponge gourd, pepper, chilly, sweet pepper, beet root, cow pea, corriander, onion, watermelon, musk melon, and flower seeds; cotton seeds; and oil seeds, including castor, groundnut, sesamum, mustard, and soyabean seeds.

It also provides cumin and isabgul spices seeds; pulses seeds comprising val, gram, black gram, and green gram seeds; and cereals seeds consisting of wheat, maize, bajra, and pegeon pea seeds. It also exports its products. The company was incorporated in 2004 and is based in Ahmedabad, India.

Stock analysis

Indo Us Bio-Tech Limited (INDOUS) currently trades at ₹66.20, while our model-based Fair Value estimate is ₹90.90, implying the stock looks roughly 27% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹178.06 per share, and 13 of the 17 models we run sit above the ₹66.20 price.

Bear case: the Asset-Based group reads lowest at ₹39.96, and 4 of the 17 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹45.12 (bear) to ₹155.30 (bull), the price of ₹66.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Basic Materials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Indo Us Bio-Tech Limited reported revenue of ₹1.1B in FY2026 versus ₹501M in FY2022, a compound +21.9%/yr. Reported net income was ₹131M in FY2026, compounding +26.9%/yr from FY2022.

Key figures

Market cap ₹1.3B (≈ $14.1M) Micro · P/E ratio 29.7 · P/S ratio 3.53 · EPS (TTM) ₹2.23 · Net margin 11.9% · Return on equity 15.3% · Return on assets (EBIT) 9.8% (5-year average) · Operating margin 13.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).

What moves the price

The share trades about 56% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at 17% fair-value upside, at 37%, INDOUS screens cheaper than that median.

Fair Value models

Bear ₹45.12 Fair Value ₹90.90 Bull ₹155.30
Price ₹66.20 · Upside +37.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹1.41 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV ₹61.12 ₹69.22 ₹75.98 74
Residual Income ₹42.59 ₹52.38 ₹79.99 72
Owner Earnings ₹45.12 ₹90.90 ₹176.16 69
All 17 models by family
DCF Models
Owner Earnings ₹45.12 ₹90.90 ₹176.16 69
Earnings-Based
Graham-Dodd ₹44.50 ₹308.30 ₹432.54 60
Lynch FV ₹90.90 ₹129.86 ₹168.81 58
PEG = 1.0 ₹90.90 ₹129.86 ₹168.81 55
EPV ₹61.12 ₹69.22 ₹75.98 74
Dividend Discount
Gordon GGM ₹0.0200 ₹0.0400 ₹0.0600 64
DDM Multi-Stage ₹0.0200 ₹0.0400 ₹0.0400 65
Multiples
P/E Multiple ₹103.07 ₹137.43 ₹171.79 63
P/S Multiple ₹66.09 ₹88.12 ₹110.15 58
P/B Multiple ₹190.36 ₹253.81 ₹317.26 55
EV/EBIT ₹87.01 ₹121.16 ₹155.30 66
EV/EBITDA ₹67.30 ₹94.87 ₹122.44 67
EV/Revenue ₹42.41 ₹67.20 ₹91.98 53
Asset-Based
NCAV (Graham) ₹26.37 ₹39.96 ₹49.95 54
Economic Profit
Residual Income ₹42.59 ₹52.38 ₹79.99 72
ROIC Compounder ₹69.87 ₹95.68 ₹117.64 69
Growth Earnings
Growth-Adj P/E ₹124.64 ₹178.06 ₹231.48 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 55
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 34
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.4%
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+25.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.1%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 15%
2026 sits 59% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Watch INDOUS, get fair value alerts →

Compare Indo Us Bio-Tech Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 174 stocks

Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside +37.3% · Top 25%
Profitability
Return on equity (12 months) 15.3% · Top 25%
Return on assets 9.9% · Top 25%
Net margin (12 months) 10.2% · Top 25%
Operating margin (12 months) 13.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 7.2% · Above median
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Agricultural Inputs median · lower = cheaper

P/E (12 months) 29.7× · Priciest 25%
P/B 1.44× · Pricier than median
P/S (12 months) 1.18× · Pricier than median
EV/EBITDA 8.2× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)83 · sector 17
FUTURE (revenue growth)36 · sector 16
PAST (return on equity)61 · sector 25
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Indo Us Bio-Tech Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Indo Us Bio-Tech Limited Fair Value". https://www.fairvalue-calculator.com/stock/INDOUS

Frequently asked questions

Is Indo Us Bio-Tech Limited (INDOUS) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of ₹90.90 versus a price of ₹66.20, about +37% upside (undervalued).
What is the fair value of INDOUS?
Our model-based fair value for Indo Us Bio-Tech Limited is ₹90.90 (as of Nov 15, 2026), built from audited fundamentals. The current price: ₹66.20.
What is the quality score of INDOUS?
Indo Us Bio-Tech Limited has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Indo Us Bio-Tech Limited (INDOUS)?
Our model-based price target is the fair value of ₹90.90 (as of Nov 15, 2026) from 17 valuation models. Cautious scenario ₹45.12, optimistic scenario ₹155.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Indo Us Bio-Tech Limited stock forecast for 2026?
Our models put fair value at ₹90.90, about +37% upside versus a price of ₹66.20 (undervalued). Cautious scenario ₹45.12, optimistic scenario ₹155.30. The calculation is refreshed regularly with new filings.
What is the revenue of Indo Us Bio-Tech Limited (INDOUS)?
Indo Us Bio-Tech Limited reported trailing-twelve-month revenue of about ₹1.1B (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Indo Us Bio-Tech Limited (INDOUS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Indo Us Bio-Tech Limited it is ₹90.90 per share (as of Nov 15, 2026), against a price of ₹66.20. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Indo Us Bio-Tech Limited stock overvalued or undervalued in 2026?
As of Nov 15, 2026, INDOUS trades below its calculated fair value: price ₹66.20, fair value ₹90.90, a gap of about +37% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INDOUS?
No. The price is what the market pays today (₹66.20); the fair value is what the company's own numbers justify (₹90.90). For Indo Us Bio-Tech Limited the two are ₹24.70 per share apart. That gap is exactly why we show both numbers side by side.
How much is Indo Us Bio-Tech Limited worth?
The market values Indo Us Bio-Tech Limited at about ₹1.3B (market capitalisation, as of Nov 15, 2026). Per share that is ₹66.20; our models calculate a fair value of ₹90.90 per share.
What do the bullish and bearish scenarios say about INDOUS?
Our models span a range for Indo Us Bio-Tech Limited: cautious scenario ₹45.12, base ₹90.90, optimistic ₹155.30 per share (as of Nov 15, 2026, price ₹66.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of INDOUS?
Indo Us Bio-Tech Limited trades at a price-to-earnings ratio of 29.7 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹90.90 is built from several models across several years. Other multiples: P/B 1.4, P/S 1.2, EV/EBITDA 8.2.
How solid is the balance sheet of Indo Us Bio-Tech Limited (INDOUS)?
Balance-sheet figures for Indo Us Bio-Tech Limited (as of Nov 15, 2026): return on equity 15.3%, debt of 0.01 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is INDOUS from its 52-week high?
Indo Us Bio-Tech Limited trades at ₹66.20, about 56% below its 52-week high of ₹150.72 and 10% above the low of ₹60.31 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹90.90 is for.
Which stocks are comparable to Indo Us Bio-Tech Limited?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, SABIC Agri-Nutrients Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Indo Us Bio-Tech Limited stock attractive at the current price?
The data as of Nov 15, 2026: price ₹66.20, calculated fair value ₹90.90 (+37%), Quality Score 47/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INDOUS calculated?
We run Indo Us Bio-Tech Limited through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹90.90 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Indo Us Bio-Tech Limited currently trades 27% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Indo Us Bio-Tech Limited (INDOUS)?
The closing price on Nov 16, 2026 was ₹66.20. Our model-based fair value is ₹90.90, about +37% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Indo Us Bio-Tech Limited right now?
The large discount to fair value meets weak quality (47/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide (₹45.12 to ₹155.30). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Indo Us Bio-Tech Limited

How large is the market capitalisation of Indo Us Bio-Tech Limited (INDOUS)?
The market capitalisation of Indo Us Bio-Tech Limited is ₹1.3B (≈ $14.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Indo Us Bio-Tech Limited (INDOUS)?
The price-to-sales ratio of Indo Us Bio-Tech Limited is 3.53 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Indo Us Bio-Tech Limited (INDOUS)?
Earnings per share at Indo Us Bio-Tech Limited are ₹2.23 (price ÷ EPS = P/E 29.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Indo Us Bio-Tech Limited (INDOUS)?
The net margin of Indo Us Bio-Tech Limited is 11.9% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Indo Us Bio-Tech Limited (INDOUS)?
The return on equity (ROE) of Indo Us Bio-Tech Limited is 15.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Indo Us Bio-Tech Limited (INDOUS)?
On an EBIT basis the return on assets of Indo Us Bio-Tech Limited is 9.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Indo Us Bio-Tech Limited (INDOUS)?
The operating margin of Indo Us Bio-Tech Limited is 13.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Indo Us Bio-Tech Limited (INDOUS)?
Revenue at Indo Us Bio-Tech Limited is growing 7.2% versus a year earlier (3y avg +21.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Indo Us Bio-Tech Limited (INDOUS)?
Earnings per share at Indo Us Bio-Tech Limited are down 35.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Indo Us Bio-Tech Limited (INDOUS) generate?
The free cash flow of Indo Us Bio-Tech Limited is −₹150M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Indo Us Bio-Tech Limited (INDOUS) carry?
The net debt of Indo Us Bio-Tech Limited is ₹309M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Indo Us Bio-Tech Limited in the live analysis

One click puts Indo Us Bio-Tech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.